Lynx1 Capital Management LP C4 Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $279 Million
- Q3 2024
A detailed history of Lynx1 Capital Management LP transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 6,880,527 shares of CCCC stock, worth $29.7 Million. This represents 14.04% of its overall portfolio holdings.
Number of Shares
6,880,527Holding current value
$29.7 Million% of portfolio
14.04%Shares
5 transactions
Others Institutions Holding CCCC
# of Institutions
130Shares Held
63.5MCall Options Held
670KPut Options Held
54.8K-
Soleus Capital Management, L.P. Greenwich, CT6.6MShares$28.5 Million3.2% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT5.68MShares$24.5 Million0.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$21 Million0.39% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$19.6 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.38MShares$18.9 Million0.59% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $211M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...